What question did this study set out to answer?

The aim is to create a survival prognostic model for patients with high-risk myelodysplastic syndrome (MDS) receiving decitabine.

April 15, 2026Open Access

A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine

Key Points

The aim is to create a survival prognostic model for patients with high-risk myelodysplastic syndrome (MDS) receiving decitabine.
Analysis of clinical variables, including age and bone marrow blasts.
Evaluation of cytogenetic and mutational factors.
Development of a prognostic model incorporating these variables.
Identified key factors affecting prognosis, such as age and cytogenetics.
The model may improve individualized treatment strategies for high-risk MDS patients.

Abstract

Decitabine provides short-term hematologic benefits in high-risk MDS, but overall prognosis remains poor. Age, bone marrow blasts, iron overload, and high-risk cytogenetics are key prognostic factors. Incorporating clinical, cytogenetic, and mutational variables into new prognostic models may enhance individualized treatment decision-making for high-risk MDS patients.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Yi Liu

Haiyue Niu

Yansong Wei

Journals

Hematology

Actions

Institutions

Capital Medical University

Tianjin Medical University General Hospital

Beijing Friendship Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study